Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.

Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, Triebel F, Charron D, Aoudjit F, Al-Daccak R, Michel L.

J Immunol. 2011 May 1;186(9):5173-83. doi: 10.4049/jimmunol.1002050.

2.
3.

HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells.

Aoudjit F, Guo W, Gagnon-Houde JV, Castaigne JG, Alcaide-Loridan C, Charron D, Al-Daccak R.

Exp Cell Res. 2004 Sep 10;299(1):79-90.

PMID:
15302575
6.

MHC class II-mediated antigen presentation by melanoma cells.

Brady MS, Eckels DD, Ree SY, Schultheiss KE, Lee JS.

J Immunother Emphasis Tumor Immunol. 1996 Nov;19(6):387-97.

PMID:
9041456
7.

Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.

Röhn TA, Schadendorf D, Sun Y, Nguyen XD, Roeder D, Langen H, Vogt AB, Kropshofer H.

Eur J Immunol. 2005 Oct;35(10):2826-39.

9.

Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy.

Méndez R, Ruiz-Cabello F, Rodríguez T, Del Campo A, Paschen A, Schadendorf D, Garrido F.

Cancer Immunol Immunother. 2007 Jan;56(1):88-94.

PMID:
16622680
10.

Suppression of FasL expression in tumor cells and preventing TNF-induced apoptosis was better for immune cells survival.

Xu G, Zhang J.

J Cancer Res Clin Oncol. 2008 Oct;134(10):1043-9. doi: 10.1007/s00432-008-0393-3.

PMID:
18461366
11.

Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.

Frost PJ, Butterfield LH, Dissette VB, Economou JS, Bonavida B.

J Immunol. 2001 Mar 1;166(5):3564-73.

12.

Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.

Rivoltini L, Radrizzani M, Accornero P, Squarcina P, Chiodoni C, Mazzocchi A, Castelli C, Tarsini P, Viggiano V, Belli F, Colombo MP, Parmiani G.

J Immunol. 1998 Aug 1;161(3):1220-30.

13.

Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.

Meissner M, Whiteside TL, van Kuik-Romein P, Valesky EM, van den Elsen PJ, Kaufmann R, Seliger B.

Br J Dermatol. 2008 May;158(5):930-40. doi: 10.1111/j.1365-2133.2008.08465.x.

PMID:
18284388
15.

Effect of tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells.

Hsiao YW, Liao KW, Hung SW, Chu RM.

Vet Immunol Immunopathol. 2002 Aug;87(1-2):19-27.

PMID:
12052339
16.

[Role of MHC class I molecules in anti-tumoral mechanisms in human malignant melanoma].

Dissemond J, Grabbe S.

Hautarzt. 2006 Aug;57(8):690-6. Review. German.

PMID:
16163561
17.

NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients.

Maccalli C, Nonaka D, Piris A, Pende D, Rivoltini L, Castelli C, Parmiani G.

Clin Cancer Res. 2007 Dec 15;13(24):7459-68.

18.

Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway.

Di Carlo E, Cappello P, Sorrentino C, D'Antuono T, Pellicciotta A, Giovarelli M, Forni G, Musiani P, Triebel F.

J Pathol. 2005 Jan;205(1):82-91.

PMID:
15586367
19.

CIITA transformation rescues the apoptotic function of MHC class II in melanoma cells.

Le E, Zhang H, Blanck G.

Anticancer Res. 2005 Nov-Dec;25(6B):3889-92.

20.

Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.

Radosevich M, Song Z, Gorga JC, Ksander B, Ono SJ.

Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3185-95.

PMID:
15326139
Items per page

Supplemental Content

Support Center